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Objectives: To evaluate functional outcomes of aripiprazole once-monthly 
(ARI-OM) 400 mg (ARI-OM-400) versus a sub-therapeutic dose of ARI-OM (50 mg; 
ARI-OM-50), oral aripiprazole (ARI), and placebo, in two trials of stable patients with 
schizophrenia. MethOds: Detailed study designs have been reported previously. 
Results are reported for the double-blind, randomized phase of each study. ARI-OM 
is an extended-release injectable suspension given at 400 mg in the gluteal muscle. 
Functional outcome was measured using the Personal and Social Performance scale 
(PSP) and statistically analyzed using analysis of covariance with last observation 
carried forward. Results: A total of 403 patients were randomized to ARI-OM-400 
(n= 269) or placebo (n= 134) in the first (246) trial. PSP scores at endpoint significantly 
worsened with placebo (-6.2) versus ARI-OM-400 (-1.7; p= 0.0002). In the second 
study (247), 662 patients were randomized to: ARI-OM-400 (n= 265); ARI (n= 266); 
or ARI-OM-50 (n= 131). PSP scores with sub-therapeutic ARI-OM-50 significantly 
worsened (-2.39) versus ARI-OM-400 (+0.45; p= 0.03). Similar functional stability 
was observed with ARI (+0.08). cOnclusiOns: Patient functioning, as assessed 
by PSP, was maintained with ARI-OM in both studies but deteriorated in patients 
randomized to either sub-therapeutic doses or placebo, confirming the benefits of 
adequately dosed antipsychotic therapy in preserving functional stability in long-
term management of schizophrenia.
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Objectives: Mild cognitive impairment (MCI) is a state that lies between normal 
cognition and dementia, and the number of cases with the condition is rising as the 
population ages. However, to date, no validated patient reported outcome measure 
(PRO) exists specifically in MCI. We report on a study to develop a PRO for use in 
MCI. MethOds: Semi-structured in-depth interviews were carried out with peo-
ple with MCI in order to determine the questionnaire items. These interviews were 
audio-recorded, transcribed and content analysed. The draft questionnaire was 
refined following feedback from a focus group of patients with a diagnosis of MCI. 
Questionnaires were posted to subjects recruited from memory clinics and research 
databases, the completed questionnaires were analysed using factor analytic tech-
niques to produce the final measure; construct validity was assessed by correlation 
with a generic patient reported outcome measure, the SF-12. Results: Interviews 
were carried out with 23 people with MCI. 280 questionnaires were sent to subjects, 
with a response rate of 56% i.e.146 were included in the analysis. Factor analysis 
produced a 13 item measure tapping two domains of patient reported quality of life 
(‘Emotional Effects’ and ‘Practical Concerns’ ). Internal consistency reliability was high 
for both domains (alpha was 0.91 and 0.85 respectively). Both dimensions were found 
to be highly and significantly correlated with the Mental Component Summary score 
of the SF-12. cOnclusiOns: The Mild Cognitive Impairment Questionnaire (MCQ) is 
a short 13 item measure developed specifically to measure patient reported outcomes 
in people with MCI. It was created on the basis of patient report, and has been shown 
to have good psychometric properties. It is likely to prove valuable in the evaluation 
of treatment regimes in this important and growing patient group.
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Objectives: To guide researchers on the best way to score the Center for 
Epidemiologic Studies – Depression scale (CES-D) by comparing competing mod-
els in the literature. MethOds: Radloff (19777), the original CES-D author, first 
provided scoring for four uncorrelated factors of depression: negative affect 
(NA), positive affect (PA), interpersonal (I), and somatic (S). Sheehan et al. (1995) 
validated four correlated factors in the CES-D. However, Radloff and Sheehan 
results may have differed because Radloff ascribed items of failure and fearfulto 
NA whereas Sheehan assigned a value of I. Following Sheehan’s scoring, Cole et 
al. (2004) presumed a hierarchical factor of depressed mood that included all four 
previously identified factors and posited a 10-item short-form of the CES-D. These 
four models were compared using structural equation modeling for parametric 
models with Bollen-Stine bootstraps to control for multivariate nonnormality in 
225 community-residing subjects, structural validity of the models were com-
pared. Results: Fit statistics for the four models were: Radloff comparative fit 
index (CFI) = .790 & root mean square error of approximation (RMEA) = .011; 
Sheehan CFI = .926 & RMSEA = .053, Cole hierarchical CFI = .927 & RMSEA = 
.052; Cole 10-item CFI = .979 & RMSEA = .041 cOnclusiOns: The uncorrelated 
Radloff model was the poorest fit the day. Both Sheehan and Cole 20-item models 
were decently fit to the data and nearly identical to each other in fit. Finally, the 
10-item Cole short-form of the CES-D was the best fit model to the data. Given 
the brevity of this form and strong fit with the theoretical structure postulated 
by Radloff, researchers may want to consider this form of the CES-D for research 
on depressed mood.
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Objectives: Although depression is a significant co-morbid condition in chronic 
illness, little is known about the prevalence or risk factors for depressive symp-
cohorts were matched 1:1 using “nearest neighbor” greedy match propensity score 
method. HRU (inpatient, outpatient, and medications) and costs were compared 
between the two cohorts. Unit costs were identified from German Diagnosis-related 
Group for inpatient, Einheitlicher Bewertungsmassstab doctor fee scale for out-
patient, and Rote Liste®for medication costs. Direct medical costs over the post-
index period were reported in 2011 Euros. Chi-square for categorical variables and 
t-test or Wilcoxon-Mann-Whitney for continuous variables were used to test for 
differences between cohorts (alpha= 0.05). Generalized linear models with nega-
tive binomial (for HRU) and gamma (for cost) distributions were used to address 
residual differences between matched cohorts. Results: Of 4705 eligible patients, 
737 with ATX (mean age= 10.9 years, 20.8% female) were identified and matched 
1:1 with LA-MPH patients (mean age= 11.2 years, 18.6% female). Patients initiating 
ATX had higher HRU and spending per-patient than patients initiating LA-MPH 
over the post-index: 20.9 (SD= 11.5) vs. 15.7 (SD= 9.0) outpatient prescriptions, 10.1 
(SD= 6.3) vs. 8.3 (SD= 5.3) outpatient visits, € 1029 (SD= 574) vs. € 496 (SD= 334) in retail 
pharmacy costs, and € 1,258 (SD= 739) vs. € 684 (SD= 515) in total all-cause costs (all 
p= < .0001). cOnclusiOns: Among children/adolescents with ADHD in Germany, 
ATX initiators consumed significantly more health care resources and were associ-
ated with significantly higher direct medical costs compared with LA-MPH initiators.
MenTal HealTH – Patient-reported outcomes & Patient Preference studies
PMH48
faCTors assoCiaTeD wiTH Poor aDHerenCe in PaTienTs iniTiaTing 
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Objectives: To examine factors associated with low adherence in Major Depressive 
Disorder (MDD) patients initiating antidepressant medication (ADM) over a 12-week 
period. MethOds: MDD patients initiating an ADM (with no ADM claim in the 6 
months prior) were identified from a large pharmacy benefits manager database. 
Patients completed paper or online assessments including demographics at baseline 
and patient-reported assessments at baseline, Week 4 and Week 12. Participants were 
classified as having low, medium, or high adherence based on the modified Morisky 
Adherence Scale, with the medium and high adherence groups combined for analysis. 
Logistic regression analyses were run to evaluate the association between adherence 
and age, gender, and patient-reported assessments of depression and sexual dysfunc-
tion (SD), weight gain, sleep problems, nausea, and anxiety. Results: Of 2412 patients 
screened, 591 enrolled and completed baseline assessments. Mean age was 40.4 years 
(standard deviation= 12.1), 82.4% were women, and 87.6% were white. There were 483 
who completed Week 4 and 425 who completed Week 12 assessments. At Week 12, 
39.6% were high adherers, 20.6% were medium adherers, and 39.8% were low adher-
ers. Thirty-eight percent of low adherers had actually discontinued ADM. Among dis-
continuers, 40.6% discontinued due to ADM side effects. In logistic regression models, 
low adherence at Week 4 was significantly associated with weight change ≥ 5 pounds 
(OR= 2.10, 95% CI: 1.32–3.35), anxiety (OR= 1.73, 95% CI: 1.06-2.8) and nausea (OR= 2.31, 
95% CI: 1.06–5.02). Age, gender, depression severity, sexual dysfunction, and insomnia 
were not significant in the logistic model. No factors were significantly associated 
with adherence at Week 12. cOnclusiOns: In this real-world study of patients with 
MDD, nearly 40% of patients were low adherers. Weight change, anxiety, and nausea 
were associated with low adherence at Week 4, but not at Week 12.
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Objectives: This study examined patterns of adherence, switching, and discontinu-
ation, in major depressive disorder (MDD) patients initiating antidepressant medica-
tion (ADM) therapy. MethOds: Depressed patients recently initiating an ADM were 
identified from a large pharmacy benefits manager database. Eligible patients were 
invited to participate by phone or mail and enrolled patients completed. Results: 
Of 2,412 patients screened, 591 were enrolled. Average age was 40.4 years (standard 
deviation= 12.1), 82.4% of participants were women, and 87.6% were white. At Week 
4 (n= 483), 39.4% were classified as low adherers with 31 (6.4%) patients having 
discontinued ADM for reasons including side effects (n= 14, 45.2%), feeling better 
(n= 5, 16.1%), cost (n= 5, 16.1%), and lack of efficacy (n= 4, 12.9%). There were 27 (5.6%) 
patients who switched by Week 4. Of these, 12 (44.4%) switched due to side effects, 
11 (40.7%) due to lack of efficacy, and 3 (11%) due to cost. By week 12 (n= 425), 33 
additional patients had discontinued ADM citing similar reasons as those at Week 
4. Of 43 patients who reported switching at Week 4 or Week 12, 15 (34.9%) cited side 
effects, 16 (37.2%) cited lack of efficacy, and 4 (9.3%) cited cost. cOnclusiOns: In 
this real-world, 12-week study of MDD patients initiating ADM, adherence to ADM 
was low. Switching and discontinuing ADM were common within the 12-weeks 
period and were primarily attributed to side effects and lack of efficacy.
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Objectives: To evaluate health-related quality of life (HRQOL) and contributing 
factors in individuals receiving opiate replacement therapy. MethOds: This was 
a cross-sectional study of patients attending for methadone therapy in an inner 
city drug treatment centre. EQ-5D, SF-36, SF-6D, Hospital Anxiety Depression Scale 
(HADs) were assessed, along with substance abuse via the Treatment Outcomes 
Profile (TOPs). Mean values, ranges and standard deviations were calculated and 
utility scores were derived. Analysis was performed using Spearman’s correlation 
and t-test to determine any significant correlations. Results: A total of 115 patients 
were included, 72% were male and the mean age was 35 years. 63% were HCV-PCR 
positive and 49% admitted to using drugs in the past month. 57% of patients had 
high levels of anxiety with the mean score being 11.14 (anxious). 35% were depressed 
with the mean score being 8.40 (borderline depressed). The mean EQ-5D utility 
score was 0.56 with 7% having a utility score that was worse than death. The mean 
SF-36 utility score was 0.55. The mean SF-36 physical component score was 44.25 
and the mean mental component score was 33.18. cOnclusiOns: HRQOL was 
reduced in this opiate replacement therapy cohort. HCV, gender and injecting drug 
use did not affect HRQOL but anxiety, depression and use of crack cocaine had a 
significant impact.
MenTal HealTH – Health Care use & Policy studies
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Objectives: Describe the management of alcohol dependence at general practitioner 
(GP) level. MethOds: STREAM is a non-interventional, 6-month prospective study of 
adult patients undergoing targeted alcohol screening during routine consultation by 
GPs throughout England and Scotland, for whom alcohol problems were either known 
or suspected on the basis of clinical signs or patient’s report. Inclusion criteria were an 
AUDIT score > = 8 and consent. At baseline, diagnosis of dependence was made using 
the DSM-IV criteria and data were collected on socio-demographic characteristics, co-
morbidities, alcohol consumption with the timeline follow-back method, previous and 
current alcohol treatment, treatment goal (abstinence or reduction of alcohol consump-
tion). The data were analyzed descriptively. Results: A total of 218 patients screened 
positive and were included in 26 sites. A total of 79% of patients fulfilled the DSM-IV 
criteria for alcohol dependence; 74% were men, the mean age was 50 years and only 
29% were working full or part-time. 40% of patients had a history of alcohol treatment 
(almost always counseling), 20% had a history of detoxification and 9% a history of 
pharmacological treatment. At inclusion, the proportion of patients with ongoing treat-
ment for alcohol addiction was 28% and these patients were drinking in average 63 g/
day compared to 89 g/d in untreated patients. Of those patients on treatment or about 
to initiate it, alcohol reduction was more frequently the treatment goal than abstinence 
(51% vs. 45%). cOnclusiOns: Targeted screening is an effective way for GPs to identify 
patients with alcohol dependence opportunistically. Many such patients have a history 
of counseling but few have received pharmacological interventions. Only a minority of 
those with alcohol dependence have ever received any form of treatment. For the major-
ity of those in treatment, alcohol reduction is the treatment goal of choice. Consumption 
levels in patients with dependence tend to be high, irrespective of treatment status.
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Objectives: Elderly people facing dependence are exposed to the financial risk of 
long lasting care expenditures. This risk is high for people facing cognitive, func-
tional and behavioral problems. In the short-term, dependent elderly people face 
increased non-medical care expenditures. In the long-term, they face increase medi-
cal care expenditures, driven by extended hospital stays. In France, providing public 
financial assistance has been showed to improve dependent people’s access to 
non-medical care services. However, the long-term impact of public financial assis-
tance on care trajectories has not been explored yet. Our study aims at determining 
whether financial assistance on non-medical care provision decreases hospital stays 
rates. MethOds: We run Fixed Effects Poisson regression models using longitudinal 
data of 574 French patients diagnosed with Alzheimer’s disease. We use instrumen-
tal variables to reduce the presence of a potential endogeneity bias. Results: We 
find that beneficiaries of home care subsidies have a 34% lower rate of hospitaliza-
tion than non-beneficiaries. cOnclusiOns: Providing public financial assistance 
is effective to reduce hospitalizations in Alzheimer’s disease.
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Objectives: The increasing prevalence of dementia worldwide highlights the need 
for effective and individualized support systems for dementia treatment and care. 
Facing the reality of increasing internet usage as well as the large availability of 
digitalized information, there is a high potential for ehealth interventions. Therefore 
one purpose of this project is to provide a ‘Personal eHealth Knowledge Space’ (PeKS) 
toms in chronic obstructive pulmonary disease (COPD) in India. A study was 
undertaken to investigate the prevalence and risk factors of depression in the 
Indian COPD patients. MethOds: COPD was classified according to GOLD stages 
based on forced expiratory volume in one second (FEV1) in 126 stable patients. 
Depression was examined by administering the nine-item Hindi version of Patient 
Health Questionnaire-9 (PHQ-9). Linear regression model was used to examine 
association between predictor variables and risk of depression with adjustment 
of age and sex. Cronbach alpha was calculated to assess internal consistency of 
PHQ-9. Results: Patients with stable COPD (n= 126) were evaluated (73.8% male 
and 26.2% female). In the study population as whole, 33.3% patients showed mod-
erate to severe depressive symptoms whereas 20.6% patients had major depressive 
disorder on PHQ-9 Scale. Educational and occupational status, body mass index, 
FEV1, respiratory symptoms, physical impairment and dyspnea were found to be 
potential predictors of depression in COPD patients. cOnclusiOns: One-fifth of 
the patients with COPD had severe symptoms of related to depression, which was 
especially higher with severity of COPD. Hence, the patients with COPD should 
focus on management of these two conditions. Further, future studies should be 
conducted to assess the role of depression management and timely treatment of 
it in the patients with COPD.
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Objectives: To analyze the effect of adding pregabalin or usual care (UC) on 
patient functioning in GAD subjects with partial response (PR) to previous SSRI 
course in daily medical practice. MethOds: Post-hoc analysis of patients with PR 
to SSRI monotherapy enrolled in a prospective 6-month naturalistic study. PR was 
defined as a Clinical Global Impression scale score > 3 and persistence of anxiety 
symptoms > 16 in the Hamilton-Anxiety scale. Two groups (based on psychiatrist 
judgment) were analyzed: adjunctive therapy (AT) with pregabalin (150-600 mg/
day) to existing therapy; or usual care (switching to a different SSRI or adding 
another anxiolytic different than pregabalin). Patient functioning was assessed by 
mean of the disability WHO-DAS-II scale [range 0 (no disability) to 100 (completely 
unable)]. Changes in domains scale scores were compared at end-of-trial visit by 
a general linear model with covariates. Results: Four-hundred-eighty-six newly 
prescribed pregabalin and 239 UC patients [mean (SD) HAM-A 26.7 (6.9) and CGI 4.1 
(0.5)] were analyzed. AT with pregabalin was associated with significantly higher 
mean (95% CI) reductions vs. UC in all the domains of the WHO-DAS-II scale. 
Differences between groups were statistically significant (effect sizes were moder-
ate): understanding and communication [-6.9(-9.8;-4.0), p< 0.001], getting around 
[-5.2(-8.0;-2.8), p< 0.001], self-care [-3.6(-5.5;-1.8), p< 0.001], getting along with oth-
ers [-5.0(-8.6;-1.3), p= 0.007], household [-5.3(-9.6;-1.0), p= 0.015], work activities 
[-6.5(-11.2;-1.8), p= 0.007], and participation in society [-6.3(-9.7;-2.9), p< 0.001]. The 
overall disability score was significantly more reduced in pregabalin group vs. 
UC: -21.7(-23.3;-20.1) vs. -15.3(-17.5;-13.1), p< 0.001. Gender effect was negligible 
(no interaction) in all the dimensions analyzed except household functioning 
(higher reduction in women). cOnclusiOns: In medical practice, GAD patients 
with partial response to prior course of a SSRI experienced greater and meaningful 
functioning improvements with adjunctive therapy with pregabalin in comparison 
with usual care. The effect of pregabalin was independent of patient gender except 
for household functioning.
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Objectives: The effect of mental disorders on absenteeism in Germany has stead-
ily increased. They are now the third-most common reason for sick leave after 
musculoskeletal and respiratory conditions. The aim of this study was to provide 
current estimates of the effect of anxiety and depression on both absenteeism 
and presenteeism in Germany. MethOds: Data from the German respondents 
(N= 15,001) of the 2011 National Health and Wellness Survey were used in the 
analysis. Outcome measures included the Short Form-12v2 (mental and physi-
cal component summary [MCS and PCS] and health utility scores) and the Work 
Productivity and Activity Impairment questionnaire. Respondents who reported 
a diagnosis of anxiety and, separately, a diagnosis of depression were compared 
with respective matched controls (matched on demographic and health his-
tory variables using propensity score matching). Results: A total of 904 (6.0%) 
respondents reported a diagnosis of anxiety (62.6% female, mean age= 44.6 years) 
and 1574 (10.5%) respondents reported a diagnosis of depression (60.2% female; 
mean age= 44.9 years). Compared with matched controls, respondents with anxi-
ety reported significantly greater absenteeism (17.9% vs. 8.1%) and presenteeism 
(36.3% vs. 19.4%) (all p< .05). Similar findings were observed for depression (absen-
teeism: 17%.3 vs. 7.6%; presenteeism: 36.1% vs. 17.1%; all p< .05). These findings 
translated to an incremental 60.7 and 61.1 days lost per year due to absenteeism 
alone for anxiety and depression, respectively. Respondents with anxiety and 
depression also reported significantly lower levels of health status compared 
with matched controls (anxiety: 33.0 vs. 45.7 and 43.5 vs. 46.6 for MCS and PCS, 
respectively, all p< .05; depression: 33.3 vs. 46.6 and 43.8 vs. 47.1 for MCS and PCS, 
respectively, all p< .05). cOnclusiOns: Anxiety and depression were associated 
with significant work impairment along with reduced mental and physical health 
status in Germany. These results suggest greater awareness and early treatment 
could reduce the social and economic burden of these conditions.
